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Background: Hyponatraemia is a common finding in patients with cancer, and has been shown to be associated
with poor prognosis in different settings. We have analysed the impact of severe hyponatraemia in patients with
cancer.
Methods: A retrospective review of all patients admitted to a specialist cancer hospital with a plasma sodium of
less than 115 mmol/l and a diagnosis of malignancy was undertaken. Patient and tumour characteristics were
analysed as well as impact of hyponatraemia management on overall survival and number of lines of cancer
treatment received.
Results: 57 patients were identified. 84% had advanced Stage 3 or 4 cancer and approximately 85% with data available
had symptoms attributable to hyponatraemia. Mean length of hospital stay was 12 days, and overall survival (OS) was
5.1 months. Plasma sodium level corrected in 56% of patients and here OS was 13.6 months compared to 16 days in
those whose sodium did not correct (p < 0.001). Those whose sodium corrected were more likely to receive further
lines of anti-cancer treatment.
Conclusions: Severe hyponatraemia in cancer is associated with very poor survival, but correction of the sodium level
leads to additional treatment and significantly greater overall survival (although it is not possible to determine if this is
due to specific therapy of the hyponatraemia or the resolving hyponatraemia reflects an improvement in the clinical
condition). Aggressive treatment of hyponatraemia may allow more anti-cancer treatment and improve survival.
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Hyponatraemia, defined as a serum sodium level of less
than 135 mmol/L, is widely reported to be the most com-
mon electrolyte abnormality amongst hospitalised patients
affecting at least 5% of inpatients [1]. Even mild hypona-
traemia has been shown to be associated with increased
mortality amongst inpatients [2,3]. Patients may present
with a variety of signs and symptoms ranging from leth-
argy, nausea, headaches and potentially seizures and coma
due to cerebral oedema [4]. These features are reversible
on correction of the serum sodium level.
Treatment of hyponatraemia varies according to the vol-
ume status of the patient. Hypovolaemic hyponatraemia is
conventionally treated with intravenous saline rehydration.* Correspondence: sanjay.popat@rmh.nhs.uk
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unless otherwise stated.When the underlying cause of hyponatraemia is Syndrome
of Inappropriate Antidiuretic Hormone (SIADH), fluid re-
striction and in some countries, demeclocycline, urea or di-
uretics have been mainstays of treatment, with hypertonic
saline tending to be reserved for life-threatening situations
as these treatment options are often slow to instigate,
poorly tolerated and ineffective [5]. However, more recent
consensus statements have tended to support more aggres-
sive treatment and the wider use of hypertonic saline [6,7].
Vasopressin-2 receptor antagonists, also known as the ‘Vap-
tans’, have now been licensed as a novel treatment option
for SIADH [8]. These non-peptide vasopressin receptor an-
tagonists block V2 receptors and decrease aquaporin 2 ac-
tivity in the kidney, thereby reducing reabsorption and
increasing diuresis of free water [9]. However their use in
SIADH remains controversial, in part due to the lack
of hard outcome data showing they reduce mortality [6].entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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setting of malignancy and is most often a paraneoplastic
phenomenon due to ectopic Antidiuretic hormone
(ADH) release [10]. Tumour types commonly associated
with SIADH are small-cell lung cancer (SCLC), (10-15%
of cases are associated with SIADH), squamous cell car-
cinomas of the head and neck, and lymphomas [11].
Excess release of atrial natriuretic peptide (either as a
stress response or a paraneoplastic phenomenon is an-
other possible mechanism for hyponatraemia in cancer
patients [12].
Hyponatraemia is also a predictive marker of longer
hospital stays and greater costs [1]. Previous studies have
shown that the increased risk of mortality with hypona-
traemia is also observed with hyponatraemia in cancer
patients [13]. More recent data has confirmed both an
increased 90-day mortality and length of hospital stay in
cancer patients with hyponatraemia, recorded either on
admission or during their stay [14]. In this reported
dataset, although there was an increased mortality in
those with mild hyponatraemia (serum sodium between
130 and 134 mmol/L) it was more pronounced with
more severe hyponatraemia. The 90-day mortality was
lower in those in whom the hyponatraemia improved
during the admission. However, this study only included
a small number of patients with severe hyponatraemia,
defined as serum sodium <115 mmol/L. It remains un-
clear if hyponatraemia directly contributes to the in-
creased mortality or is a marker of the severity of
underlying illness. It is also unclear if hyponatraemia is
associated with overall mortality, as opposed to 90-day
mortality, and whether correction of hyponatraemia
predicts better overall survival (OS). It is plausible, espe-
cially in patients with cancer, that correction of hypona-
traemia may lead to better survival rates, for example by
contributing to improved performance status and hence
suitability to receive anti-cancer treatment.
In this study we have examined a large cohort of
patients with severe hyponatraemia, admitted to a spe-
cialist cancer hospital. Length of hospital stay and over-
all survival were examined, as well as the types of
malignancy, and survival was compared between those
whose hyponatraemia resolved and those where it did
not. This study was approved as a service evaluation by
the Royal Marsden Hospital Clinical Audit Committee.
Methods
We performed a retrospective analysis of all patients at
the Royal Marsden Hospital with a confirmed malig-
nancy and at least one episode of severe hyponatraemia
(serum sodium level of <115 mmol/L) over a five-year
period (1st January 2007 to 1st January 2012). Patients
were identified using biochemistry databases and elec-
tronic patient records reviewed to obtain data. Fieldsincluding patient age, date of cancer diagnosis, primary
tumour site, histology, stage, date of initial severe hypo-
natraemia, documented symptoms of hyponatraemia,
date of normalisation, initial urea and creatinine level
and other basic biochemistry, duration of hospital ad-
mission, admission to the intensive care unit (ICU), and
date of death or last follow-up were collected. In
addition data on the number of lines of anti-cancer
treatment (chemotherapy, radiotherapy or surgery) were
collected.
The primary endpoint of the study was to determine
the median duration of hospitalisation in patients with
severe hyponatraemia. Secondary endpoints included
overall survival from the date of detection of severe
hyponatraemia, time to normalisation, overall survival in
those whose sodium did normalize compared to those
who did not, and the distribution of different primary
tumour sites and stage.
OS was calculated from the date of first biochemical
evidence of severe hyponatraemia to date of death from
any cause. Any surviving patients were censored at date
of last follow-up. OS was illustrated by means of Kaplan
Meier curves for the whole patient population and for
stratification by sodium levels. The log-rank test was
used to assess survival differences for patients in whom
sodium level normalized compared with those in whom
it did not. Cox regression was used to obtain hazard ra-
tio for death. A multivariate analysis was performed
using age and gender as prognostic factors. Performance
status was poorly documented and therefore not in-
cluded in this analysis.
Any differences in the number of patients receiving
anti-cancer treatment at the time of profound hypona-
traemia between the cohorts of patients with corrected
and uncorrected sodium levels were assessed by Fisher’s
exact test. Differences between the same cohorts for the
number of lines of anti-cancer treatment received were
assessed using Mann–Whitney test.
This study was exempt from Ethics committee approval
at our institution and was classified as a Service Evalu-
ation. It was approved as such by the Royal Marsden
Hospital Clinical Audit Committee.
Results
A total of 60 patients were identified with a sodium
of <115 mmol/L. On review of clinical records 3
were excluded (1 due to lack of a diagnosis of malig-
nancy, and 2 due to a high likelihood of erroneous hypo-
natraemia results). Of the remaining 57 patients, mean
age was 60 +/− 15 (range 18–88).
The distribution of tumour primary site is shown in
Table 1. The stage of malignancy at time of diagnosis of
severe hyponatraemia was available in 45 patients (95%).
The majority (84%) of patients had Stage 3 or 4 disease.
Table 1 Distribution of primary tumour site amongst
patients with severe hyponatraemia
Primary tumour site Number %
Gastrointestinal 18 31.7
Lung 10 17.5
Haematological 6 10.6
Breast 6 10.5
Other* 6 10.7
Urological 5 8.8
(Gynae)cological 4 7.1
Head and neck 2 3.5
*Others consists of carcinoma of unknown primary, melanoma and sarcoma.
Balachandran et al. BMC Cancer  (2015) 15:163 Page 3 of 5The histological type of tumour was determined: 38.6%
of all cases were adenocarcinomas, whilst 12.3% were
SCLC. Surprisingly only 1 patient (1.8%) had squamous
cell carcinoma.
40.4% of patients had potential symptoms recorded.
15.8% of patients were asymptomatic and the reason for
admission was varied including bowel obstruction, elect-
ive retroperitoneal lymph node dissection and ureteric
stenting of hydronephrosis. Admission occurred for cor-
rection of the asymptomatic hyponatraemia with fluid
balance monitoring. Of those with symptoms, lethargy
(14.0%), nausea-vomiting (14.0%) and confusion (10.5%),
were the commonest. 50 out of 57 patients with severe
hyponatraemia were admitted to hospital. The reasons
for not admitting the remaining 7 patients are not re-
corded. Amongst those admitted, the median length of
stay was 12 days +/− 15 (range 0 to 201 days). ICU
admission was required in 4 patients (7%) who had ad-
missions lasting 21, 32, 43 and 68 days respectively.Figure 1 Kaplan-Meier curves for overall survival in patients developi
in all patients developing severe hyponatraemia. b: Kaplan-Meier curve for ov
normalisation of sodium level.Key: Na + normalized: Green – Yes; Blue – No.Further clinical information including other biochemis-
try, volume status and hyponatraemia specific therapy,
where available, is shown in Additional file 1.
The sodium level returned to normal in 32 patients
(56%). The median time to resolution of hyponatraemia
was 16 days (range 0–692). OS in this cohort of patients
with severe hyponatraemia was poor, at a median of
5.1 months (95% CI: 1.8 to 8.4 months, Figure 1a). In
those whose sodium level returned to normal, median
OS was 13.6 months (95% CI: 2.6 to 24.5 months), com-
pared to 16 days (95% CI: 2.6 to 29.4 days) in those
where it did not correct (Figure 1b, HR = 0.2 95% CI:
0.1-0.4, p < 0.001). After adjusting for age and gender in
a multivariate model, normalisation of sodium remained
significant (HR = 0.2 95% CI 0.1-0.3, p < 0.001).
There was no significant difference (p = 0.19) in the
number of patients receiving anti-cancer treatment
(chemotherapy, radiotherapy or surgery) at the time of
profound hyponatraemia between the cohorts of pa-
tients with corrected and uncorrected sodium levels.
More patients in those whose sodium normalised
received 1 or more subsequent lines of anti-cancer
therapy (median 1, range 0–3) than those in whom the
Na did not normalise (median 0, range 0–1). This was
significant (p < 0.001).
Discussion
This study has examined a large cohort of patients
with cancer and severe hyponatraemia (serum sodium
level <115 mmol/L). We have confirmed the very poor
survival in these patients, extending this to examine OS
rather than the previously reported in-hospital mortality
or 90 day mortality [11]. This study also confirms previousng severe hyponatraemia. a: Kaplan-Meier curve for overall survival
erall survival in all patients developing severe hyponatraemia stratified by
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proved survival [11]. It is not possible to determine if this
reflects an effect of specific therapy for hyponatraemia or
the resolving hyponatraemia reflects improvements in the
underlying condition. However, the number of treatment
lines received after profound hyponatraemia was signifi-
cantly increased in the cohort of patients with a normal-
ised sodium level versus those in whom it was not
normalised. It is thus possible that treatment of hypona-
traemia improves performance status allowing patients to
receive systemic anti-cancer treatment. This may, in part,
explain the dramatic differences in overall survival
(13.6 months median in those whose sodium improved
compared to 16 days in those who remained hyponatrae-
mic). Given this difference in overall survival, there is an
unmet clinical need for therapy to treat and potentially
improve the outcome for patients with profound hypona-
traemia that did not normalise.
We have also demonstrated that the vast majority of
oncology patients with severe hyponatraemia have
advanced cancer, with 84% having stage 3 or 4 disease.
Perhaps surprisingly, nearly a third of patients had
gastrointestinal tract malignancies, with only 17.5% having
lung cancer. This is likely to be underpinned by several
potential biases, including a greater proportion of patients
overall treated for gastrointestinal cancers or increased
toxicity from systemic therapy for gastrointestinal malig-
nancies such as diarrhoea-associated hyponatraemia.
A further limitation of this retrospective study was the
inability to distinguish the different causes of hypona-
traemia, and it may be that if a cohort with confirmed
SIADH was examined, a greater proportion would have
had SCLC and head and neck tumours. Also surpris-
ingly, the most frequent histology was adenocarcinoma,
whilst only 12.3% had SCLC, and 1.8% squamous cell
cancers, despite these being the histological subtypes
thought to be most frequently associated with SIADH.
Similarly, given the retrospective nature of the data, it is
not possible to comment on the relative effects of differ-
ent treatments of hyponatraemia on outcomes.
As hyponatraemia often presents with non-specific
features or even in the absence of symptoms, it is pos-
sible that it is poorly recognised and this potential
under-diagnosis should be considered when reviewing
our data. Nevertheless this is one of the largest cohorts
reported with severe hyponatraemia in cancer patients,
and we have reported outcomes of OS by hyponatraemia
resolution.
Historically, the treatment of hyponatraemia due to
SIADH has been challenging, whilst the treatment of
hypovolaemic hyponatraemia is generally straightfor-
ward, but novel treatments such as vasopressin-2 antag-
onists may be important in enabling treatment in
patients who, prior to correction of their hyponatraemia,would not have had a performance status sufficient to
permit chemotherapy. Thus, prompt correction of
hyponatraemia, including the use of vasopressin-2 re-
ceptor antagonists in patients with SIADH may result
in improved OS, and this is an important hypothesis
that would benefit from further investigation in inter-
vention trials.
Conclusions
We have confirmed that severe hyponatraemia in the
setting of malignancy is associated with a very poor OS
and that resolution of hyponatraemia correlates with
significantly better survival (although it is not possible to
determine if this is due to specific therapy of the hypo-
natraemia) and suitability for more subsequent treat-
ment lines compared to persistent hyponatraemia. This
raises the question of whether effective treatment of the
underlying hyponatraemia in patients with cancer may
improve outcomes.
Additional file
Additional file 1: Table showing additional clinical data on patients
with severe hyponatraemia, including urea and creatinine levels at
time of diagnosis of hyponatraemia, clinical assessment of volume
status (where known) and hyponatraemia specific therapies (where
known).
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